These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 17441915

  • 21. Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.
    Shaheen PE, Rini BI, Bukowski RM.
    Clin Genitourin Cancer; 2006 Jun; 5(1):78-81. PubMed ID: 16859583
    [Abstract] [Full Text] [Related]

  • 22. Kidney cancer: Does hypothyroidism predict clinical outcome?
    Rini B.
    Nat Rev Urol; 2011 Jan; 8(1):10-1. PubMed ID: 21116300
    [No Abstract] [Full Text] [Related]

  • 23. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S, Bjelogrlic SK.
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [Abstract] [Full Text] [Related]

  • 24. Major treatment improvements encourage kidney cancer researchers to seek further gains.
    Tuma RS.
    J Natl Cancer Inst; 2008 Sep 03; 100(17):1202-3. PubMed ID: 18728277
    [No Abstract] [Full Text] [Related]

  • 25. Re: Börje Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jaques Patard and Ioanel C. Sinescu. Renal cell cacinoma guideline. Eur Urol 2007;51:1502-10.
    Di Lorenzo G.
    Eur Urol; 2007 Sep 03; 52(3):926-8; author reply 928. PubMed ID: 17574728
    [No Abstract] [Full Text] [Related]

  • 26. Molecular biology of renal cell carcinoma.
    Mellado B, Gascón P.
    Clin Transl Oncol; 2006 Oct 03; 8(10):706-10. PubMed ID: 17074668
    [Abstract] [Full Text] [Related]

  • 27. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
    Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG.
    J Urol; 2008 Jul 03; 180(1):94-8. PubMed ID: 18485389
    [Abstract] [Full Text] [Related]

  • 28. New therapeutic approaches in the management of metastatic renal cell carcinoma.
    Gkialas IK, Papadopoulos G.
    J BUON; 2009 Jul 03; 14(3):399-404. PubMed ID: 19810129
    [Abstract] [Full Text] [Related]

  • 29. [Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma].
    Miller K, Bergmann L, Albers P, Jäger E, Jakse G, Geschwend JE, Marschner N.
    Aktuelle Urol; 2007 Jul 03; 38(4):328-30. PubMed ID: 17647172
    [Abstract] [Full Text] [Related]

  • 30. Targeting von Hippel-Lindau pathway in renal cell carcinoma.
    Patel PH, Chadalavada RS, Chaganti RS, Motzer RJ.
    Clin Cancer Res; 2006 Dec 15; 12(24):7215-20. PubMed ID: 17189392
    [Abstract] [Full Text] [Related]

  • 31. VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.
    Rini BI.
    Curr Oncol Rep; 2006 Mar 15; 8(2):85-9. PubMed ID: 16507216
    [Abstract] [Full Text] [Related]

  • 32. [New drugs; sunitinib and sorafenib].
    van Bronswijk H, Dubois EA, Osanto S, Cohen AF.
    Ned Tijdschr Geneeskd; 2007 Dec 29; 151(52):2888-90. PubMed ID: 18257434
    [Abstract] [Full Text] [Related]

  • 33. Targeted therapy in renal cell carcinoma.
    Vakkalanka BK, Rini BI.
    Curr Opin Urol; 2008 Sep 29; 18(5):481-7. PubMed ID: 18670271
    [Abstract] [Full Text] [Related]

  • 34. [Molecular targeted therapy for renal cell carcinoma and other urological cancers].
    Miyake H, Fujisawa M.
    Nihon Rinsho; 2010 Oct 29; 68(10):1871-5. PubMed ID: 20954332
    [Abstract] [Full Text] [Related]

  • 35. Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development.
    Rini BI, Sosman JA, Motzer RJ.
    BJU Int; 2005 Aug 29; 96(3):286-90. PubMed ID: 16042715
    [No Abstract] [Full Text] [Related]

  • 36. Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies.
    Strumberg D.
    J Clin Oncol; 2008 Jul 10; 26(20):3469-71; author reply 2471. PubMed ID: 18612169
    [No Abstract] [Full Text] [Related]

  • 37. Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
    Bukowski RM.
    Clin Genitourin Cancer; 2009 Jan 10; 7(1):9-10. PubMed ID: 19213661
    [No Abstract] [Full Text] [Related]

  • 38. Renal cell carcinoma: today's targeted therapies improving tomorrow's outcomes.
    Biedrzycki BA.
    ONS News; 2006 Jan 10; 21(8 Suppl):21-2. PubMed ID: 16925136
    [No Abstract] [Full Text] [Related]

  • 39. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
    Tamaskar I, Garcia JA, Elson P, Wood L, Mekhail T, Dreicer R, Rini BI, Bukowski RM.
    J Urol; 2008 Jan 10; 179(1):81-6; discussion 86. PubMed ID: 17997441
    [Abstract] [Full Text] [Related]

  • 40. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
    Grandinetti CA, Goldspiel BR.
    Pharmacotherapy; 2007 Aug 10; 27(8):1125-44. PubMed ID: 17655513
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.